PFE's sell-off triggers a rich dividend yield of 6.73% and double digits capital appreciation prospects, thanks to management's focus to "enhancing long-term shareholder value." Despite the patent ...

Pfizer's EPS and revenue beat my expectations, mainly due to strong sales of its anti-cancer medications. So, Xtandi sales amounted to $565 million in the fourth quarter of 2024, an increase of 79....

Pfizer Stock's Upside Got Bigger

Pfizer (PFE -0.43%) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent times. Thanks to its coronavirus treatment and vaccine, the pharma giant ...

I rate Pfizer a sell for the next 18–24 months. I expect continued headwinds from Medicare Part D redesign and patent expirations for Eliquis and Prevnar-13 in 2026. Medicare changes will cut $1 bi...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® ...

Pfizer's business is facing material revenue shrink issues due to many patent expirations over the next 3 years. Quarterly revenue run rate analysis suggests management may be underestimating the i...

I have downgraded Pfizer Inc. stock to Strong Sell due to stagnant revenue, substantial patent cliffs, regulatory, legal, and reputational headwinds, and overvaluation concerns. Despite a 24.7% YoY...

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that...

Pfizer chairman and CEO Albert Bourla sees cancer as Pfizer's next big chance to save the world. The complexity of cancers makes treatments expensive to develop and challenging to customize, but th...

The past three years have been difficult for Pfizer (PFE -0.35%). The pharmaceutical giant's financial results worsened substantially as its coronavirus-related tailwind came to a screeching halt.

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 pe...

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

NEW YORK--(BUSINESS WIRE)--Pfizer Fourth-Quarter and Full-Year 2024 Earnings Release.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafen...